CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial

Abstract Background Adjuvant therapy improves the prognosis of stage II & III colon cancer patients. Unfortunately, most patients do not benefit from this treatment. PePITA (NCT00994864) is a prospective, multicenter, non-randomized study whose primary objective is to predict the outcome of adju...

Full description

Bibliographic Details
Main Authors: Françoise Rothé, Marion Maetens, Ghizlane Rouas, Marianne Paesmans, Marc Van den Eynde, Jean-Luc Van Laethem, Philippe Vergauwe, Guido Deboever, Yacine Bareche, Caroline Vandeputte, Michail Ignatiadis, Alain Hendlisz
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Cancer
Online Access:http://link.springer.com/article/10.1186/s12885-019-5528-1

Internet

http://link.springer.com/article/10.1186/s12885-019-5528-1

Similar Items